Drug Approvals, Breakthrough Treatments and Royalties - Research Report on Celgene Corporation, Onyx Pharmaceuticals, Sarepta Therapeutics, VIVUS and Achillion Pharmaceuticals

Fri Mar 8, 2013 8:01am EST

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link
below:

http://pdf.reuters.com/pdfnews/pdfnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130308:nPn3086433


NEW YORK,  March 8, 2013  /PRNewswire/ --

Today, Investors Alliance announced new research reports highlighting Celgene
Corporation (NASDAQ: CELG), Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX), Sarepta
Therapeutics, Inc. (NASDAQ: SRPT), VIVUS Inc. (NASDAQ: VVUS) and Achillion
Pharmaceuticals, Inc. (NASDAQ: ACHN). Today's readers may access these reports
free of charge - including full price targets, industry analysis and analyst
ratings - via the links below.

Celgene Corporation Research Report

The optimism for Celgene has been pushing the stock to trade on the green in
recent sessions. Celgene was hailed by the European Organization for Rare
Diseases (EURODIS) for its excellence in medical innovation in rare diseases.
The company is now considered as the leader in the treatment of rare illnesses,
such as cancer and other severe, immune and inflammatory conditions. Celgene
also received positive results for oral Apremilast after it achieved statistical
significance for the primary endpoint of PASI-75 in the first Phase III study
(ESTEEM 1) in patients with Psoriasis. Celgene is expecting annual revenue of 
$12 billion  by 2017. The Full Research Report on Celgene Corporation -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge
at:[http://www.Investors-Alliance.com/r/full_research_report/d457_CELG  ]

--

Onyx Pharmaceuticals, Inc. Research Report

After Onyx reported new sales record for its Kyprolis, the company's first
wholly-owned product, carcinoma-treatment Nexavar posted strong regional growth
as it exceeded  $1 billion  in sales. Onyx looks poised for long-term growth
after the US Food and Drug Administration (FDA) approved Stivarga. In 2012, Onyx
received  $8 million  in royalty revenues from Bayer for the total sales of
Stivarga. The FDA approval is expected to rake in bigger royalties for Onyx
while the company continues its research and development for breakthrough
treatments. The Full Research Report on Onyx Pharmaceuticals, Inc. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.Investors-Alliance.com/r/full_research_report/ffcf_ONXX]

--

Sarepta Therapeutics, Inc. Research Report

Finding a treatment for Marburg Virus, a severe and potentially fatal disease
classified as a Category A bioterrorism agent, is a great challenge to Sarepta
as it collaborates with the US Army Medical Research Institute to formulate a
cure for the hemorrhagic fever. Sarepta's AVI-7288 received positive results
after conducting a non-human primate study to test the efficacy of the drug. The
company administered AVI-7288 via intramuscular injection which is considered as
the best way to utilize the cure in a mass casualty situation. The success of
AVI-7288 is expected to be massive once it is approved by the FDA since its
major clients may include various governments and  Africa  where Marburg Virus
is considered an endemic. The Full Research Report on Sarepta Therapeutics, Inc.
- including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.Investors-Alliance.com/r/full_research_report/cfa4_SRPT]

--

VIVUS Inc. Research Report

Qsymia, considered as one of the most successful obesity treatments from VIVUS,
showed great results after a study on weight loss and cardiovascular disease
risk factors. VIVUS reported that weight loss resulting from treatment with
Qsymia helped the improvement of cholesterol, blood pressure and triglycerides
related conditions. The positive results were greater among patients who
recorded an average of 10% in weight loss. VIVUS is expected to earn a bigger
market share because of this breakthrough obesity treatment. The Full Research
Report on VIVUS Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge
at:[http://www.Investors-Alliance.com/r/full_research_report/8ed8_VVUS]

--

Achillion Pharmaceuticals, Inc. Research Report

Achillion is conducting the Phase II clinical trial consisting of sovaprevir and
ACH-3102 during the second quarter of 2013. The company has been actively
working up its research and development to gain new approvals from the US Food
and Drug Administration (FDA). Achillion is one of the leading companies for the
research and development of Hepatitis C Virus (HCV) treatments. The company is
known for developing small molecule drugs for the treatment of the most
challenging infectious diseases. The Full Research Report on Achillion
Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.Investors-Alliance.com/r/full_research_report/0af0_ACHN]

--

Consider Investors Alliance

Tired of hearing about the latest, greatest trade opportunity... only to realize
that the ship has long sailed? You need a strong, informative community in your
arsenal. Join the group that has been consistently identifying momentous
situations as they develop - long before they become the next top news on major
financial networks.

Contact:  Patricia Byers

Email:  press@investors-alliance.com

Main: +1-(480)-745-7826

SOURCE  Investors-Alliance

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.